In Vitro Susceptibility of Multi-Drug Resistant Strains Causing Nosocomial Infections to Fosfomycin. A Comparison of Determination Methods

Overview

Journal Pathogens

Date 2021 Apr 30

PMID 33922754

Citations 10

Authors

Beata Maczynska

Justyna Paleczny

Monika Oleksy-Wawrzyniak

Irena Choroszy-Krol

Marzenna Bartoszewicz

Affiliations

Soon will be listed here.

Abstract

Introduction: Over the past few decades, strains increased their pathogenicity and antibiotic resistance, thereby becoming a major therapeutic challenge. One of the few available therapeutic options seems to be intravenous fosfomycin. Unfortunately, the determination of sensitivity to fosfomycin performed in hospital laboratories can pose a significant problem. Therefore, the aim of the present research was to evaluate the activity of fosfomycin against clinical, multidrug-resistant strains isolated from nosocomial infections between 2011 and 2020, as well as to evaluate the methods routinely used in hospital laboratories to assess bacterial susceptibility to this antibiotic.

Materials And Methods: 43 multidrug-resistant strains isolates from various infections were tested. All the strains had ESBL enzymes, and 20 also showed the presence of carbapenemases. Susceptibility was determined using the diffusion method (E-test) and the automated system (Phoenix), which were compared with the reference method (agar dilution).

Results: For the reference method and for the E-test, the percentage of strains sensitive to fosfomycin was 65%. For the Phoenix system, the percentage of susceptible strains was slightly higher and stood at 72%. The percentage of fosfomycin-resistant strains in the carbapenemase-producing group was higher (45% for the reference method and E-test and 40% for the Phoenix method) than in carbapenemase-negative strains (25%, 25%, and 20%, respectively). Full (100%) susceptibility categorical agreement was achieved for the E-test and the reference method. Agreement between the automated Phoenix system and the reference method reached 86%.

Conclusions: Fosfomycin appears to be the antibiotic with a potential for use in the treatment of infections with multidrug-resistant strains. Susceptibility to this drug is exhibited by some strains, which are resistant to colistin and carbapenems. The E-test, unlike the Phoenix method, can be an alternative to the reference method in the routine determination of fosfomycin susceptibility, as it shows agreement in terms of sensitivity categories and only slight differences in MIC values. The Phoenix system, in comparison to the reference method, shows large discrepancies in the MIC values and in the susceptibility category.

Citing Articles

Medical Device-Associated Biofilm Infections and Multidrug-Resistant Pathogens.

Bouhrour N, Nibbering P, Bendali F Pathogens. 2024; 13(5).

PMID: 38787246 PMC: 11124157. DOI: 10.3390/pathogens13050393.

Evaluation of the susceptibility of clinical isolates of NDM-producing to new antibiotics included in a treatment regimen for infections.

Slabisz N, Lesnik P, Janc J, Fidut M, Bartoszewicz M, Dudek-Wicher R Front Microbiol. 2024; 15:1331628.

PMID: 38646622 PMC: 11027895. DOI: 10.3389/fmicb.2024.1331628.

Clinical Features and Outcomes of VAP Due to Multidrug-Resistant spp.: A Retrospective Study Comparing Monobacterial and Polybacterial Episodes.

Adukauskiene D, Ciginskiene A, Adukauskaite A, Koulenti D, Rello J Antibiotics (Basel). 2023; 12(6).

PMID: 37370375 PMC: 10295231. DOI: 10.3390/antibiotics12061056.

Evolution of Antibiotic Resistance in and Clinical Isolates in a Multi-Profile Hospital over 5 Years (2017-2021).

Maczynska B, Frej-Madrzak M, Sarowska J, Woronowicz K, Choroszy-Krol I, Jama-Kmiecik A J Clin Med. 2023; 12(6).

PMID: 36983414 PMC: 10058544. DOI: 10.3390/jcm12062414.

Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.

Kowalska-Krochmal B, Maczynska B, Ruranska-Smutnicka D, Secewicz A, Krochmal G, Bartelak M Pathogens. 2022; 11(12).

PMID: 36558775 PMC: 9786176. DOI: 10.3390/pathogens11121441.

References

Hirakawa H, Kurabayashi K, Tanimoto K, Tomita H . Oxygen Limitation Enhances the Antimicrobial Activity of Fosfomycin in Following Overexpression of Which Encodes Glycerol-3-Phosphate/Fosfomycin Symporter. Front Microbiol. 2018; 9:1950. PMC: 6110920. DOI: 10.3389/fmicb.2018.01950. View

Babiker A, Clarke L, Doi Y, Shields R . Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature. Diagn Microbiol Infect Dis. 2019; 95(3):114856. DOI: 10.1016/j.diagmicrobio.2019.06.008. View

Lubbert C, Lippmann N, Busch T, Kaisers U, Ducomble T, Eckmanns T . Long-term carriage of Klebsiella pneumoniae carbapenemase-2-producing K pneumoniae after a large single-center outbreak in Germany. Am J Infect Control. 2014; 42(4):376-80. DOI: 10.1016/j.ajic.2013.12.001. View

Cao Y, Peng Q, Li S, Deng Z, Gao J . The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic. RSC Adv. 2022; 9(72):42204-42218. PMC: 9088020. DOI: 10.1039/c9ra08299a. View

Williams P . Potential of fosfomycin in treating multidrug-resistant infections in children. J Paediatr Child Health. 2020; 56(6):864-872. DOI: 10.1111/jpc.14883. View

Wang L, Di Luca M, Tkhilaishvili T, Trampuz A, Gonzalez Moreno M . Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against and Biofilms. Front Microbiol. 2019; 10:2522. PMC: 6853019. DOI: 10.3389/fmicb.2019.02522. View

Perdigao-Neto L, Oliveira M, Rizek C, Carrilho C, Costa S, Levin A . Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. Antimicrob Agents Chemother. 2013; 58(3):1763-7. PMC: 3957874. DOI: 10.1128/AAC.02048-13. View

Kaase M, Szabados F, Anders A, Gatermann S . Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J Clin Microbiol. 2014; 52(6):1893-7. PMC: 4042753. DOI: 10.1128/JCM.03484-13. View

Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A . Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013; 57(3):1421-7. PMC: 3591882. DOI: 10.1128/AAC.01718-12. View

10.

Doi Y, Murray G, Peleg A . Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015; 36(1):85-98. PMC: 4465586. DOI: 10.1055/s-0034-1398388. View

11.

Gopichand P, Agarwal G, Natarajan M, Mandal J, Deepanjali S, Parameswaran S . In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections. Infect Drug Resist. 2019; 12:2005-2013. PMC: 6628599. DOI: 10.2147/IDR.S207569. View

12.

Munoz-Price L, Poirel L, Bonomo R, Schwaber M, Daikos G, Cormican M . Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013; 13(9):785-96. PMC: 4673667. DOI: 10.1016/S1473-3099(13)70190-7. View

13.

Lu P, Hsieh Y, Lin J, Huang J, Yang T, Lin L . Characterisation of fosfomycin resistance mechanisms and molecular epidemiology in extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates. Int J Antimicrob Agents. 2016; 48(5):564-568. DOI: 10.1016/j.ijantimicag.2016.08.013. View

14.

MacDonald J, Chibabhai V . Evaluation of the RESIST-4 O.K.N.V immunochromatographic lateral flow assay for the rapid detection of OXA-48, KPC, NDM and VIM carbapenemases from cultured isolates. Access Microbiol. 2020; 1(5):e000031. PMC: 7470286. DOI: 10.1099/acmi.0.000031. View

15.

Doyle D, Peirano G, Lascols C, Lloyd T, Church D, Pitout J . Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol. 2012; 50(12):3877-80. PMC: 3503014. DOI: 10.1128/JCM.02117-12. View

16.

Fiett J, Baraniak A, Mrowka A, Fleischer M, Drulis-Kawa Z, Naumiuk L . Molecular epidemiology of acquired-metallo-beta-lactamase-producing bacteria in Poland. Antimicrob Agents Chemother. 2006; 50(3):880-6. PMC: 1426447. DOI: 10.1128/AAC.50.3.880-886.2006. View

17.

Bouxom H, Fournier D, Bouiller K, Hocquet D, Bertrand X . Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?. Int J Antimicrob Agents. 2018; 52(1):100-103. DOI: 10.1016/j.ijantimicag.2018.03.014. View

18.

Falagas M, Vouloumanou E, Samonis G, Vardakas K . Fosfomycin. Clin Microbiol Rev. 2016; 29(2):321-47. PMC: 4786888. DOI: 10.1128/CMR.00068-15. View

19.

Putensen C, Ellger B, Sakka S, Weyland A, Schmidt K, Zoller M . Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019; 47(5):827-836. DOI: 10.1007/s15010-019-01323-4. View

20.

Jiang Y, Shen P, Wei Z, Liu L, He F, Shi K . Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents. 2014; 45(1):66-70. DOI: 10.1016/j.ijantimicag.2014.08.010. View